A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations
Phase of Trial: Phase I/II
Latest Information Update: 30 Aug 2019
Price : $35 *
At a glance
- Drugs DKN 01 (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Oct 2018 Status changed from not yet recruiting to recruiting.
- 02 Oct 2018 Planned initiation date changed from 31 Aug 2018 to 31 Oct 2018.
- 29 Jun 2018 New trial record